Granules India Reports Fourth Quarter And Annual Results
ECONOMY & POLICY

Granules India Reports Fourth Quarter And Annual Results

All monetary figures are in Rs million (mn). Granules India reported results for the fourth quarter and fiscal year ended 31 March 2026. Fourth quarter revenue from operations was Rs 14,706 mn, up 23 per cent year on year, with earnings before interest, tax, depreciation and amortisation of Rs 3,521 mn, up 40 per cent, and profit before tax before exceptional items at Rs 2,464 mn, up 48 per cent; net profit was Rs 2,016 mn, up 33 per cent.\n\nNorth America accounted for 72 per cent of fourth quarter revenue and Europe for 17 per cent. Finished dosages contributed 73 per cent, active pharmaceutical ingredients 13 per cent, pharmaceutical formulation intermediates 9 per cent and Peptides CDMO 5 per cent. Return on capital employed rose to 17.6 per cent in FY26 from 16.6 per cent, and net debt declined to Rs 4,021 mn, down Rs 3,040 mn year on year, leaving net debt to EBITDA at 0.34 times.\n\nOn a yearly basis, consolidated revenue was Rs 53,656 mn, up 20 per cent, with EBITDA of Rs 11,851 mn, up 25 per cent and an EBITDA margin of 22 per cent. Reported net profit for FY26 was Rs 5,950 mn, up 19 per cent year on year, and profit before tax before exceptional items was Rs 7,950 mn.\n\nThe chairman and managing director attributed the results to portfolio expansion, disciplined execution and progress on regulatory, compliance and sustainability initiatives, and noted improved earnings quality alongside advancement in complex generics and the Peptides CDMO platform. Granules India is a vertically integrated pharmaceutical company operating across active pharmaceutical ingredients, pharmaceutical formulation intermediates, finished dosages and Peptides CDMO, and serves more than 300 customers in over 80 countries. The group operates 10 manufacturing facilities, including 7 in India, 2 in the United States and 1 in Switzerland, and holds approvals from multiple regulators.

All monetary figures are in Rs million (mn). Granules India reported results for the fourth quarter and fiscal year ended 31 March 2026. Fourth quarter revenue from operations was Rs 14,706 mn, up 23 per cent year on year, with earnings before interest, tax, depreciation and amortisation of Rs 3,521 mn, up 40 per cent, and profit before tax before exceptional items at Rs 2,464 mn, up 48 per cent; net profit was Rs 2,016 mn, up 33 per cent.\n\nNorth America accounted for 72 per cent of fourth quarter revenue and Europe for 17 per cent. Finished dosages contributed 73 per cent, active pharmaceutical ingredients 13 per cent, pharmaceutical formulation intermediates 9 per cent and Peptides CDMO 5 per cent. Return on capital employed rose to 17.6 per cent in FY26 from 16.6 per cent, and net debt declined to Rs 4,021 mn, down Rs 3,040 mn year on year, leaving net debt to EBITDA at 0.34 times.\n\nOn a yearly basis, consolidated revenue was Rs 53,656 mn, up 20 per cent, with EBITDA of Rs 11,851 mn, up 25 per cent and an EBITDA margin of 22 per cent. Reported net profit for FY26 was Rs 5,950 mn, up 19 per cent year on year, and profit before tax before exceptional items was Rs 7,950 mn.\n\nThe chairman and managing director attributed the results to portfolio expansion, disciplined execution and progress on regulatory, compliance and sustainability initiatives, and noted improved earnings quality alongside advancement in complex generics and the Peptides CDMO platform. Granules India is a vertically integrated pharmaceutical company operating across active pharmaceutical ingredients, pharmaceutical formulation intermediates, finished dosages and Peptides CDMO, and serves more than 300 customers in over 80 countries. The group operates 10 manufacturing facilities, including 7 in India, 2 in the United States and 1 in Switzerland, and holds approvals from multiple regulators.

Related Stories

Gold Stories

Next Story
Products

Koemmerling opens Navi Mumbai experience centre

Koemmerling, a brand of the profine Group, has expanded its presence in the Mumbai metropolitan region with the opening of a new experience centre in Navi Mumbai and launched its Allure S46 minimal sliding door system for the Indian market.Located in CBD Belapur, the facility was inaugurated by Peter Mrosik, Owner and CEO, profine Group, along with Farid Khan, Chairman and Managing Director, profine India, and Kamal Bajaj, CEO, profine India.The company said the new centre will showcase its portfolio of uPVC and aluminium window and door systems to architects, developers and homeowners.The ina..

Next Story
Products

India's waterproofing market nears Rs 150 bn milestone

India's waterproofing industry is approaching a market size of Rs 150 billion and is expected to surpass the $2 billion milestone, according to speakers at the 2nd India International Waterproofers Conference & Expo 2026 organised by the Waterproofers Association of India (WAI) in New Delhi.The two-day event brought together more than 20 speakers, 55 international delegates and 53 exhibition booths, with discussions focusing on climate-resilient construction, advanced waterproofing technologies and international collaboration.Inaugurating the event, Durga Shanker Mishra, former Secretary, ..

Next Story
Real Estate

Dilip Buildcon Q1 FY27 Revenue at Rs 23.78 billion

Dilip Buildcon Limited reported consolidated revenue from operations of Rs 2,378 crore in Q1 FY27, along with EBITDA of Rs 429 crore and profit after tax of Rs 128 crore.Consolidated EBITDA margin stood at 18.1%, improving from 17.1% in Q4 FY26. On a standalone basis, revenue from operations was Rs 1,930 crore, EBITDA stood at Rs 199 crore and PAT was Rs 39 crore, with an EBITDA margin of 10.3%.The company’s order book stood at Rs 27,691 crore as of 30 June 2026, compared with Rs 28,830 crore as of 31 March 2026. Roads and highways accounted for 17.1% of the order book, irrigation and water ..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement